Wall Street bankers set to see bonus hikes amid volatile market - report (XLF:NYSEARCA)
Investment and commercial bankers could see their 2026 incentives jump by 10%-15% from 2025 amid record earnings driven by equity trading, underwriting, and advisory, said a report by Johnson Associates.
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
Investment and commercial bankers could see their 2026 incentives jump by 10%-15% from 2025 amid record earnings driven by equity trading, underwriting, and advisory, said a report by Johnson Associates.
Wall Street bankers set to see bonus hikes amid volatile market - report (XLF:NYSEARCA) | Seeking Alpha
georgeclerk/E+ via Getty Images
Wall Street bankers stand to see a rise in their bonuses in the wake of a volatile market, according to a recent report.
2026 is the "Year of the Bank" as results significantly outpace other sectors. Hedge funds are set to capitalize on
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
Immunovant Q1 FY2027 Earnings Preview: IMVT-1402 Progress and Cash Runway in Focus
Immunovant is set to report Q1 FY2027 results, with investors eyeing IMVT-1402 clinical updates, batoclimab's fate, and cash burn. Pipeline catalysts and valuation risks are analyzed.
July 2026 REIT Short-Selling List: Office and Retail Under Pressure, Logistics and Infrastructure Favored
In July 2026, REITs with market caps over $2 billion showed widening divergence. Office, regional retail, and hotel REITs faced short selling, while industrial logistics, single-family rental, and infrastructure REITs were favored. Analysis of interest rates, occupancy, and cap rates provides investment insights.
AC Immune H1 Results: Alzheimer's Vaccine Data on the Horizon, Cash Runway Secured Through 2027
AC Immune reported H1 2025 results with increased R&D spending and a cash runway into 2027. Key catalyst is the upcoming Phase IIb data for ACI-24.060, with partnerships with Roche and Lilly advancing.
Bloomin' Brands Beats Q2 Estimates, Raises Q3 Guidance and FY26 Outlook, Shares Rise After Hours
Bloomin' Brands reported better-than-expected revenue and profit, provided Q3 guidance, and updated its FY26 outlook. Learn how the Outback parent is managing cost pressures and its long-term growth strategy.
